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Serum angiopoietin‑like 3 levels are 
elevated in obese non diabetic men 
but are unaffected during an oral 
glucose tolerance test
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Elizabeth Sanchez1 & Jorge Eduardo Caminos1,10*
This study aimed to determine ANGPTL3 serum levels in healthy young lean and obese non‑
diabetic men during an oral glucose tolerance test (OGTT) and correlate them with anthropometric, 
biochemical and hormonal parameters. A case–control study was carried out and 30 young obese 
non‑diabetic (23.90 ± 3.84 years and BMI 37.92 ± 4.85 kg/m2) and 28 age‑matched healthy lean 
(24.56 ± 3.50 years and BMI of 22.10 ± 1.72 kg/m2) men were included in this study. The primary 
outcome measures were serum basal ANGPTL3 and ANGPTL3–area under the curve (AUC) levels. 
The percentage of body fat was measured by dual‑energy X‑ray absorptiometry and biochemical, 
hormonal and insulin resistance indices were determined. Basal ANGPTL3 and ANGPTL3–AUC 
levels were significantly elevated (p < 0.05) in young obese subjects compared with lean subjects and 
were positively and significantly associated with different anthropometric measurements. Fasting 
ANGPTL3 serum levels were positively correlated with fasting insulin, leptin, Leptin/Adiponectin 
index and triglyceride—glucose index. Moreover, ANGPTL3–AUC was negatively correlated with 
Matsuda index. In this regard, chronically high ANGPTL3 levels in young obese subjects might favor 
triglyceride‑rich lipoprotein clearance to replenish triglyceride stores by white adipose tissue rather 
than oxidative tissues.
Elevated plasma triglyceride levels are associated with increased risk of atherosclerosis and cardiovascular disease, 
a major cause of morbidity and mortality  worldwide1. Lipoprotein lipase (LPL) plays a fundamental role in the 
normal lipid metabolism and energy balance, by catalyzing the hydrolysis of the triglyceride (TG) component of 
circulating chylomicrons and very-low-density lipoprotein (VLDL) at the luminal surface of endothelial cells in 
extrahepatic tissues, to release fatty acids that can be used or  stored2–4. LPL is mainly expressed in adipose tissue 
and striated muscle (skeletal and cardiac) and its activity is regulated in a tissue-specific  manner5,6.
Different members of the angiopoietin-like (ANGPTL) family of proteins participate in the regulation of 
LPL activity, including ANGPTL3, ANGPTL4 and  ANGPTL87,8. ANGPTL3 is a secreted glycoprotein mainly 
expressed in the liver and acts as a negative regulator of LPL and endothelial lipase activity in oxidative tissues 
such as brown adipose tissue (BAT) and skeletal  muscle9. Elevated circulating levels of this hepatokine are 
known to increase plasma levels of triglycerides, high-density lipoprotein cholesterol (HDL-c) and low-density 
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lipoprotein cholesterol (LDL-c)10. In addition, Muniyappa et al., reported higher plasmatic levels of ANGPTL3 
in leptin-deficient patients with lipodystrophy when compared to healthy control  subjects11. Furthermore, leptin 
replacement therapy (metreleptin) in patients with lipodystrophy decreased significantly serum ANGPTL3 levels, 
total cholesterol and triglyceride  concentrations11.
Consistent with clinical data, preclinical studies showed that the overexpression of both ANGPTL3 and 
ANGPTL8 in mice resulted in  hypertriglyceridemia12. Moreover, plasma levels and hepatic gene expression of 
ANGPTL3 are increased in leptin-deficient ob/ob and leptin-resistant db/db mice and were associated with an 
increase in plasma triglycerides and free fatty  acids13. Additionally, leptin-deficient ob/ob mice supplemented 
with recombinant leptin, showed lower gene expression and plasmatic levels of ANGPTL3 and normalization 
of plasmatic triglyceride  levels13.
Despite ANGPTL3 was proposed as an important regulator of plasmatic lipoprotein metabolism through 
LPL inhibition, to date, contradictory results have been reported on ANGPTL3 circulating levels in obese 
 subjects2,3,14–16. Furthermore, some studies have shown that ANGPTL3 can be involved in carbohydrate metab-
olism, but the evaluation of ANGPTL3 response to oral glucose stimulation has not been clearly established 
 yet2,17–20. Therefore, the aim of this case–control study was to determine serum ANGPTL3 levels in young healthy 
lean and obese non-diabetic men in response to the oral glucose tolerance test (OGTT), a physiological imitator 
of meal stimulation. In addition, we studied the relationship between serum ANGPTL3 levels with anthropo-
metric, biochemical, hormonal and insulin resistance indices.
Materials and methods
Ethical aspects. All experimental protocols were reviewed and approved by the Ethics Review Board of 
the School of Medicine of the Universidad Nacional de Colombia (permission number 012-204-18, August 
27—2018) and a written informed consent was obtained from all study participants. All protocols were per-
formed in accordance with the Declaration of Helsinki  for Medical Research involving Human Subjects and 
approved methods.
Study population. The present investigation was conducted as a case–control study at the Department 
of Internal Medicine—Division of Endocrinology School of Medicine Universidad Nacional de Colombia. 
According to the World health organization (WHO) body mass index (BMI = kg/m2) criteria, 30 young non-
diabetic obese men (BMI ≥ 30 kg/m2) (23.90 ± 3.84 years and BMI 37.92 ± 4.85 kg/m2) and 28 young healthy lean 
men (BMI 18.50–24.99 kg/m2) (24.56 ± 3.50 years and BMI of 22.10 ± 1.72 kg/m2) were included in this  study4. 
Healthy lean individuals in the study were normotensive, euglycemic and with triglycerides and cholesterol 
levels within the normal  range21.
Subjects who met any of the following criteria were excluded from the study: current smoking, alcoholism, 
mental illness, subjects diagnosed with type 2 diabetes mellitus (T2DM), chronic kidney disease, cardiac failure, 
hepatic failure, thyroid diseases, infectious diseases among other diseases, use of approved weight lowering 
pharmacotherapy or patients with a history of gastric bypass and other bariatric surgery. Also, subjects who 
had taken drugs that affect energy metabolism, such as metformin, levothyroxine or steroids, within the last 
12 months, were excluded.
Clinical evaluation. Subjects underwent clinical and physical examination. Weight and height were deter-
mined and BMI (kg/m2) was calculated. Anthropometric data included height, hip circumference (HC), waist 
circumference (WC) and estimated measuring of body fat percent (BF%) was determined by Dual-Energy X-ray 
absorptiometry (DXA) (GE Lunar Prodigy Advance). Systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) were measured in all subjects and mean arterial pressure (MAP) were calculated.
Biochemical and hormonal analysis. All experiments started in the morning between 7:00 and 9:00 
AM after an overnight fast. All subjects were given 75 g of anhydrous glucose, dissolved in 200 mL of water, 
after overnight fasting. The subjects underwent an oral glucose tolerance test (OGTT) and blood samples were 
collected at fasting and 30, 60 and 120 min after glucose ingestion. The serum samples were separated by cen-
trifugation at 1000×g for 15 min and stored at − 80 °C until the respective assays. Serum levels of glucose (basal 
and postprandial), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipopro-
tein cholesterol (HDL-c), high-sensitivity C-reactive protein (hs-CRP) and triglycerides (TG) were determined. 
Additionally, serum levels of ANGPTL3 (basal and postprandial), serum insulin levels (basal and postprandial), 
serum levels of adiponectin and leptin, were analyzed.
Serum ANGPTL3 levels were measured using a commercial ELISA kit (Catalog Number DANL30—R&D 
Systems, Inc. USA). The intra- and inter-assay coefficients of variation (CVs) were < 4.1% and < 8.5%, respec-
tively. Serum human leptin levels were measured with a commercial ELISA kit (Catalog Number KAC2281-
ThermoFisher Scientic Inc.). The intra- and inter-assay coefficients of variation for  leptin concentrations 
were < 3.9% and < 5.3%, respectively. Likewise, serum levels of adiponectin were determined by an ELISA KIT 
(Catalog Number KHP0041-ThermoFisher Scientific Inc.) and the coefficients of intra- and inter-assay vari-
ation were < 3.8% and < 5.5% respectively. All samples were analyzed in duplicates. Insulin–Area Under the 
Curve (AUC) (µUI–mL/2 h), glucose–Area Under the Curve (AUC) (mg–dL/2 h) and ANGPTL3–Area Under 
the Curve (AUC) (ng–mL/2 h) during OGTT were calculated by trapezoidal approximation rule as described 
 elsewhere22,23.
Definitions. All subjects underwent a full physical examination and measurements of anthropometric 
parameters were performed with a standardized technique. Anthropometric measurements were taken while 
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the participants dressed in light clothing, without shoes. Body Mass Index (BMI = kg/m2) was calculated as 
weight (kg) divided by height (m) squared. Furthermore, we calculated the waist circumference (WC) to height 
ratio (WHtR), an anthropometric index for central adiposity, determined by dividing the WC by height (cm)24. 
Additionally, we measured the waist-to-hip ratio (WHipR) as described  elsewhere21.
Metabolic syndrome was defined according to the International Diabetes Federation (IDF) criteria, to which 
central obesity (defined by WC) and ethnicity is an essential component for diagnosis of the syndrome and 
required the presence of two of the following elements: fasting plasma glucose (FPG) ≥ 100 mg/dL, systolic blood 
pressure (SBP) ≥ 130 mm Hg and diastolic blood pressure (DBP) ≥ 85 mm Hg, or on antihypertensive medica-
tion, TG ≥ 150 mg/dL or on treatment, HDLc < 40 mg/dL in men and < 50 mg/dL in women, or on  treatment21. 
Additionally, borderline metabolic abnormalities for fasting glucose and high normal blood pressure (BP), as 
described by Baden et al.25. Moreover, borderline lipid profile for metabolic syndrome factor, among these, TC, 
LDLc, HDLc and TG are described  elsewhere26.
Insulin resistance was determined according to the homeostatic insulin resistance assessment model (HOMA-
IR) as described by the Matthews et al.27. Likewise, the quantitative insulin sensitivity check index (QUICKI) 
and Matsuda index for hepatic and muscle resistance/sensitivity were estimated as described  elsewhere28–30. 
Triglyceride-glucose (TyG) and TG/HDL-c indices were calculated as described  elsewhere31,32. Values of the 
leptin/adiponectin ratio (LAR) were made as Finucane et al. described in individuals with non-diabetic insulin 
 resistance33. Leptin resistance is a term commonly used to define states in which hyperleptinemia, as seen in 
obesity-related condition, results in a decreased response to  leptin34.
Statistical analysis. Descriptive data were presented as mean ± SD. Variables with normal distribution 
were compared by unpaired Student’s t-test and one-way ANOVA and repeated-measured ANOVA. Addition-
ally, a post hoc analysis was made among the groups. Mann–Whitney U test, Kruskal–Wallis one-way analysis 
of variance and Friedman test were performed for non-normal distribution variables. Pearson’s correlation coef-
ficient was used to assess of linear relationship between fasting ANGPTL3 ng/mL and ANGPTL3–AUC (ng–
mL/2 h) with different metabolic, anthropometrics and hormonal variables. A p value < 0.05 was considered to 
be statistically significant (*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001). All statistical analyses were done 
using R version 3.4.0.  Software35. Line plots and Boxplots were generated with the R BiocGenerics  package36.
Results
Experimental results. Characteristics of the study population are shown in Table 1. Young obese subjects 
showed a borderline increase of SBP, DBP and  MAP25. Additionally, obese subjects presented borderline risk fac-
tors for metabolic syndrome, including TC, LDLc, HDLc and  TG26. During the OGTT, serum glucose and insu-
lin levels were significantly higher in the obese group compare with lean group at fasting, 30, 60, and 120 min 
(Figs. 1, 2 respectively, Table 2). Glucose—AUC and insulin—AUC were significantly higher in obese compared 
with lean subjects (Figs.  1, 2, Table  2). Hyperinsulinemia and hyperleptinemia were confirmed in the obese 
subjects by the surrogated indices HOMA-IR, QUICKI, Matsuda, TyG, TG/HDL-c and LAR indices (Table 1).
Serum adiponectin levels were significantly lower (p = 0.001) in obese non-diabetic men compared to the 
healthy lean men (Table 1). In contrast, serum leptin concentrations were notably higher (p = 0.001) in obese 
non-diabetic men compared to the healthy lean men (Table 1). Mean ANGPTL3 serum levels at 0, 30, 60, and 
120 min and ANGPTL3–AUC, in response to an oral glucose tolerance test, were significantly higher (p = 0.000) 
in obese compared to healthy lean subjects (Table 2, Fig. 3). No significant difference was seen over time in 
serum ANGPTL3 levels at baseline (0), 30, 60 and 120 min during the OGTT in healthy young lean and obese 
non-diabetic men (Fig. 3).
At baseline, ANGPTL3 serum levels were significantly (but weakly) positively correlated with fasting insulin 
(r = 0.267; p = 0.043) (Table 3). Furthermore, leptin (r = 0.381; p = 0.003), LAR (r = 0.381; p = 0.003) and TyG 
indices (r = 0.285; p = 0.030) were positively correlated with fasting ANGPTL3 serum levels (Table 3, Supple-
mentary Fig. S1A–C respectively). Fasting serum ANGPTL3 levels were positively correlated with anthropomet-
ric parameters such as BMI (r = 0.413; p = 0.001), WC (r = 0.453; p = 0.000), WHtR (r = 0.435; p = 0.001), AFM 
(%) (r = 0.395; p = 0.002), TBF (%) (r = 0.395; p = 0.002), WHipR (r = 0.417; p = 0.001) and GFM (%) (r = 0.350; 
p = 0.007) (Table 3). There was no statistically significant correlation between basal serum ANGPTL3 levels and 
triglyceride levels, HOMA–IR and QUICKI indices (Table 3).
Finally, ANGPTL3-AUC was negatively correlated with Matsuda Index (r =  − 0.315; p = 0.016) and positively 
correlated with Insulin-AUC (r = 0.324; p = 0.013) (Supplementary Fig. S3A,B respectively). Similar correlations 
between ANGPTL3–AUC and anthropometric parameters such as BMI (r = 0.417; p = 0.001), WC (r = 0.459; 
p = 0.000), WHtR (r = 0.418; p = 0.001), WHipR (r = 0.418; p = 0.009), AFM (%) (r = 0.476; p = 0.000), GFM (%) 
(r = 0.428; p = 0.000) and TBF (%) (r = 0.460; p = 0.000) (Supplementary Fig. S2A–D,F respectively), were seen 
with fasting ANGPTL3 serum levels (Table 3).
Discussion
This study has demonstrated that serum ANGPTL3 levels were significantly elevated in young obese non-diabetic 
subjects compared to healthy control subjects. However, short‐term changes of serum ANGPTL3 levels at fast-
ing and OGTT (30, 60, and 120 min) remained unchanged in both groups. Thus, the present study suggests that 
serum ANGPTL3 levels do not seem to be involved in short-term regulation of carbohydrate metabolism. How-
ever, previous studies have shown that ANGPTL3 levels are abnormally increased in insulin-resistant state and 
obesity, with worsening glucose metabolism and enhancing lipolysis in adipose  tissues19,37. This could indicate 
the possible role of ANGPTL3 in regulating glucose metabolism at long-term, which could progressively lead to 
type 2 diabetes and other metabolic lifelong  diseases19,37.
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Basal serum ANGPTL3 levels were positively correlated with anthropometric parameters such as WC, BMI, 
WHipR, TBF (%), AFM (%) and GFM (%). However we did not find a significantly correlation with TG levels, 
which is in line with previously reported  results3,14, but not with others showing that circulating ANGPTL3 was 
negatively correlated with TG  levels38. The controversial relationship between ANGPTL3 levels and TG suggests 
that there are other factors affecting the interaction between ANGPTL3 levels and TGs, and further studies are 
needed to better understand this  relationship3,14,38,39. In this regard, it is worth pointing out that ANGPTL3 levels 
are significantly higher in patients with advanced forms of NAFLD or nonalcoholic steatohepatitis (NASH), but 
no significant differences were detected in individuals with simple fatty liver (NAFL) when compared to healthy 
and normal weight  individuals20. Thus, the results obtained in our study showing that ANGPTL3 levels were 
significantly higher in young obese non-diabetic individuals and could be at least partially, affected by the pres-
ence of NASH. This is relevant because the development of NASH reduces insulin clearance and could hinder 
the interpretation of plasma insulin data and derived indices.
Additionally, in this study, results showed serum ANGPTL3 levels at baseline and ANGPTL3–AUC signifi-
cantly higher in obese subjects compared to lean subjects. These data are in agreement with previous results 
reported in human obese subjects and animal  models2,13,17. In addition, plasmatic levels of ANGPTL3 were 
elevated in patients with generalized lipodystrophy and significantly reduced after metreleptin  therapy11. Our 
data indicating that fasting serum ANGPTL3 levels were positively correlated with serum leptin levels and leptin/
adiponectin index would suggest that hyperleptinemia might lead to increased serum ANGPTL3 levels in young 
obese subjects. However, different to ours, Cinkajzlová et al. have found serum ANGPTL3 levels were lower in 
obese subjects with and without T2DM when compared to healthy control  subjects16. It is important to highlight 
Table 1.  Baseline characteristics of the study population. AFM android fat mass (%), AUC area under the 
curve, BMI (kg/m2) Body Mass Index, DBP diastolic blood pressure, GFM gynoid fat mass (%), HDL-c high-
density lipoprotein cholesterol, HOMA-IR homeostatic insulin resistance assessment model, hs-CRP high-
sensitivity C-reactive protein, L/A leptin/adiponectin ratio, LDL-c low-density lipoprotein cholesterol, MAP 
mean arterial pressure, QUICKI quantitative insulin sensitivity check index, SBP: systolic blood pressure, TBF 
total body fat (%), TG triglycerides, TG/HDL-c triglyceride (TG)/high-density lipoprotein cholesterol (HDL-c) 
(TG/HDL-c ratio) index, TyG triglyceride-glucose index, VLDL-c very low-density lipoprotein cholesterol, 
WAT white adipose tissue, WC waist circumference, WHipR waist-to-hip ratio, WHtR waist circumference to 
height ratio. *A p-value < 0.05 was considered statistically significant.
Variable
Lean (n = 28)
Mean ± SD
Obese (n = 30)
Mean ± SD p value
Age (year) 24.56 ± 3.50 23.89 ± 3.88 0.480
Systolic blood pressure (SBP) 112.11 ± 10.18 129.43 ± 12.12 0.001
Diastolic blood pressure (DBP) 70.14 ± 8.10 85.03 ± 10.44 0.001
Mean arterial pressure (MAP) 84.12 ± 7.21 100.03 ± 9.71 0.001
Height (m) 1.74 ± 0.054 1.75 ± .0.065 0.412
Weight (kg) 66.79 ± 6.59 115.70 ± 15.75 0.001
BMI (kg/m2) 22.10 ± 1.72 37.92 ± 4.85 0.001
Hip (cm) 94.96 ± 3.58 123.02 ± 7.75 0.001
WC (m) 78.11 ± 4.60 110.99 ± 8.36 0.001
AFM (%) 28.93 ± 6.92 55.71 ± 3.14 0.001
GFM (%) 27.30 ± 4.72 47.37 ± 3.78 0.001
TBF (%) 14.44 ± 3.52 45.10 ± 3.70 0.001
WHtR 0.45 ± 0.03 0.63 ± 0.057 0.001
WhipR 0.82 ± 0.035 0.90 ± 0.054 0.001
Leptin (ng/mL) 7.54 ± 1.03 23.43 ± 7.76 0.001
Adiponectin (µg/mL) 15.14 ± 1.92 13.16 ± 1.79 0.001
Fasting glucose (mg/dL) 82.39 ± 7.97 88.53 ± 11.23 0.031
Fasting Insulin (µUI/mL) 7.83 ± 3.16 26.80 ± 11.51 0.001
Triglycerides (mg/dL) 91.75 ± 30.10 191.70 ± 98.48 0.001
HDLc cholesterol (mg/dL) 47.86 ± 7.09 40.37 ± 7.46 0.002
LDLc cholesterol (mg/dL) 98.86 ± 20.22 116.07 ± 22.82 0.003
Total cholesterol (mg/dL) 164.57 ± 23.97 189.30 ± 27.65 0.002
(hs-CRP) 1.01 ± 0.91 5.88 ± 4.15 0.001
Leptin/Adiponectin Index 0.51 ± 0.10 1.81 ± 0.63 0.001
TG/HDLc Index 1.99 ± 0.81 4.81 ± 2.63 0.001
TyG Index 8.16 ± 0.33 8.92 ± 0.48 0.001
HOMA–R Index 1.59 ± 0.64 6.41 ± 3.13 0.001
Matsuda Index 6.72 ± 2.86 2.03 ± 1.34 0.001
QUICKI Index 0.36 ± 0.023 0.30 ± 0.022 0.001
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that those results were obtained in obese subjects with metabolic syndrome, while our cohort showed borderline 
metabolic syndrome criteria risk factors. On the other hand, other studies demonstrated that ANGPTL3 levels 
did not differ significantly between overweight or obese subjects compared to normal weight  subjects14,15.
It is important to highlight that Shimamura et al. also demonstrated the negative regulation of ANGPTL3 by 
insulin  action13. In STZ-treated insulin-deficient mice, plasmatic levels and hepatic expression of ANGPTL3, 
TG and FFA levels were higher compared with control  mice13. Of note, in the current study we observed 
ANGPTL3–AUC was positively correlated with insulin–AUC and negatively correlated with the Matsuda index, 
which would imply that insulin resistance might contribute to the increased serum ANGPTL3 levels in obese 
subjects. On the other hand, the associations of basal serum levels of ANGPTL3 with fasting insulin levels and 
TyG index was found to be weak as evidenced by their low correlation coefficients which were smaller than 0.29. 
Therefore, it is evident that assessing ANGPTL3 in obese subjects will require further investigation, in particular 
performing large and well conducted clinical and epidemiological studies, stratified by age, sex, ethnicity and 
geographic region.
Recent Genome-Wide Association Studies (GWAS) and whole-exome sequencing have identified sequence 
variants associated with loss of function in the ANGPTL3 gene across populations from Europe, Asia, Africa 
and the  Americas40–46. In this way, ANGPTL3 genetic variation across populations from Europe, Asia, Africa and 
the Americas, has been studied to identify Single Nucleotide Polymorphism (SNPs) specific to each population. 
Therefore, sequence variant in the ANGPTL3 gene might have important implications for the diagnosis and 
therapeutic interventions of diseases such as combined hypolipidemia that consists of extremely low plasma levels 
of HDL-c, LDL cholesterol and  triglycerides40–46. From a genetic perspective on diversity, the population of Latin 
American is descended from indigenous American, European, and African populations. SNPs and structural 
Figure 1.  Comparison between serum glucose levels in the obese group and lean group: (A) at fasting, 30, 60, 
and 120 min and (B) serum glucose levels area under the curve (AUC) (mg/dL/2 h) in the obese group and 
lean group. Line plots and Boxplots were generated with the R BiocGenerics package. A p-value < 0.05, was 
considered statistically significant *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001.
Figure 2.  Comparison between serum insulin levels in the obese group and lean group: (A) at fasting, 30, 60, 
and 120 min and (B) serum insulin levels area under the curve (AUC) (μUI/mL/2 h) in the obese group and 
lean group. Line plots and Boxplots were generated with the R BiocGenerics package. A p-value < 0.05, was 
considered statistically significant *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001.
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variants that may be unique or specific to each population for ANGPTL3 have not been studied extensively and 
it may have important consequences for health and wellbeing.
This paper is the first study of ANGPTL3 status in young obese non-diabetic and age-matched healthy non-
obese men control in the Latino American population. However, a limitation of the study is that the possible 
prevalence of NAFLD in obese subjects, which may have an important influence in the ANGPTL3 levels that was 
not considered. In addition, only young men were enrolled in the study, with the purpose to reduce the effects 
of possible confounding variables, such as the influences of sex hormones in healthy women during normal 
menstrual cycle and in obese women with polycystic ovary syndrome (PCOS).
Table 2.  Comparison of glucose, insulin and ANGPTL3 serum levels at fasting, 30, 60 and 120 min between 
the lean and obese group. AUC area under the curve. *A p-value < 0.05 was considered statistically significant.
Variable Time
Lean (n = 28)
Mean ± SD
Obese (n = 30)
Mean ± SD p value
Glucose
0 min (mg/dL) 82.39 ± 7.97 88.53 ± 11.23 0.031
30 min (mg/dL) 115.61 ± 18.31 129.43 ± 26.68 0.027
60 min (mg/dL) 85.71 ± 16.91 116.83 ± 28.83 0.001
120 min (mg/dL) 74.64 ± 13.81 94.97 ± 24.12 0.001
Glucose–AUC 180.01 ± 24.82 221.96 ± 44.02 0.000
Insulin
0 min (µUI/mL) 7.83 ± 3.16 26.80 ± 11.51 0.001
30 min (µUI/mL) 81.46 ± 4.58 212.94 ± 9.75 0.001
60 min (µUI/mL) 54.49 ± 30.82 145.77 ± 74.07 0.001
120 min (µUI/mL) 27.46 ± 20.63 89.10 ± 68.47 0.005
Insulin–AUC 88.21 ± 32.21 267.05 ± 108.90 0.000
ANGPTL3
0 min (ng/mL) 117.20 ± 24.05 140.09 ± 33.07 0.008
30 min (ng/mL) 117.29 ± 23.90 135.6081 ± 29.87 0.013
60 min (ng/mL) 113.24 ± 25.19 141.7284 ± 31.76 0.003
120 min (ng/mL) 113.19 ± 31.85 142.5383 ± 30.81 0.002
ANGPTL3–AUC 229.48 ± 46.92 280.39 ± 55.72 0.000
Figure 3.  Comparison between serum ANGPTL3 levels in the obese group and lean group: (A) at fasting, 30, 
60, and 120 min and (B) serum ANGPTL3 levels area under the curve (AUC) (ng/mL/2 h) in the obese group 
and lean group. Line plots and Boxplots were generated with the R BiocGenerics package. A p-value < 0.05, was 
considered statistically significant *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001.
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Conclusions
In conclusion, our results indicate that in Latin American young obese individuals, circulating ANGPTL3 levels 
are higher than those non-obese healthy controls at the basal state, but these levels remained unchanged during 
an OGTT. Thus, these findings support an important role of ANGPTL3 in obesity.
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